1. P565: IMPROVED OUTCOME OF PATIENS WITH ACUTE MYELOID LEUKEMIA HARBORING FLT3 MUTATION IN THE ERA OF TARGETED THERAPY. (23rd June 2022) Authors: Oñate, G.; Pratcorona, M.; Garrido, A.; Artigas, A.; Bataller, A.; Tormo, M.; Arnan, M.; Vives, S.; Coll, R.; Salamero, O.; Vall-Llovera, F.; Sampol, A.; Garcia, A.; Cervera, M.; Garcia Avila, S.; Bargay, J.; Ortin, X.; Esteve, J.; Sierra, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 464 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPACT OF GERIATRIC ASSESSMENT AND SOMATIC MUTATIONS IN HIGH-RISK MYELODYSPLASTIC SYNDROMES NOT ELIGIBLE FOR ALO-HCST. CET-AZA-2016–1 2022 UPDATE. ON BEHALF OF THE CETLAM GROUP. (May 2023) Authors: Amer, N.; Cabezón, M.; Xicoy, B.; Garrido, A.; Baena, N.; Canet, M.; Arnan, M.; Arenillas, L.; Coll, R.; Ortin, X.; Diaz, M.; Talarn, C.; García-Caro, M.; Zamora, L.; Bargay, J. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗